Newsroom
Press Release
Press Release

White & Case Advises ADVANZ PHARMA on Acquisition of Intercept Pharmaceuticals

Global law firm White & Case LLP has advised ADVANZ PHARMA on its acquisition of the ex-US business of Intercept Pharmaceuticals. 

"This investment will give ADVANZ PHARMA the rights to commercialise Ocaliva, a drug treatment for primary biliary cholangitis, a form of liver disease, outside the US and thereby establish it as a leading provider of specialty and hospital pharmaceuticals in Europe,” said White & Case partner Mike Weir, who led the Firm's deal team. “Our role advising on this deal highlights White & Case's position as a go-to firm for private equity investments in the pharmaceuticals sector."

ADVANZ PHARMA is a specialty pharmaceutical company headquartered in London, with an operations centre of excellence in Mumbai, commercial affiliates in North America, Europe and Australia, and an established global network of commercial partners throughout the rest of the world. With an agile and experienced team, including direct sales, marketing and medical capability across many of Europe's major markets, ADVANZ PHARMA supplies, innovates and enhances the critical medicines patients depend on, ensuring continued patient access and improving health outcomes.

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept Pharmaceuticals has operations in the United States, Europe and Canada. 

The transaction is actively supported by ADVANZ PHARMA’s owner Nordic Capital, a leading private equity investor with extensive experience and expertise in the global healthcare market, which acquired ADVANZ PHARMA in June 2021.

The White & Case team that advised on the transaction was led by partners Mike Weir (London) and Andres Liivak (New York), with support from partners Philip Abelson (New York), Marc Israel, Nicholas Greenacre, Will Smith (all London), Tilman Kuhn (Dusseldorf, Brussels), Tomislav Vrabec (Frankfurt), Alexis Hojabr, Alexandre Jaurett (both Paris) and Alessandro Seganfreddo (Milan), local partners Carlos Daroca (Madrid) and Thilo-Maximilian Wienke (Dusseldorf), and associates James Turner, Ruth Taylor, Luc Rosenberg, Kate Russell, Yannis Lagdani, Emma Jell (all London), Ajita Shukla (Washington, DC), Nashel Jung (New York), Cristina Caroppo (Dusseldorf), Eojin Lie (Frankfurt), Clement Cenreaud, Dany Luu, Dorian Smida (all Paris), Sara Scapin, Lorenza Fici (both Milan), Laura del Olmo and Gracia Truan (both Madrid).

Press contact
For more information please speak to your local media contact.